CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
Subscribe To Our Newsletter & Stay Updated